000291120 001__ 291120
000291120 005__ 20250512134237.0
000291120 0247_ $$2doi$$a10.1007/s11060-024-04740-0
000291120 0247_ $$2pmid$$apmid:38900237
000291120 0247_ $$2ISSN$$a0167-594X
000291120 0247_ $$2ISSN$$a1573-7373
000291120 037__ $$aDKFZ-2024-01323
000291120 041__ $$aEnglish
000291120 082__ $$a610
000291120 1001_ $$0P:(DE-HGF)0$$aStrack, Maren$$b0
000291120 245__ $$aEffects of tumor treating fields (TTFields) on human mesenchymal stromal cells.
000291120 260__ $$aDordrecht [u.a.]$$bSpringer Science + Business Media B.V$$c2024
000291120 3367_ $$2DRIVER$$aarticle
000291120 3367_ $$2DataCite$$aOutput Types/Journal article
000291120 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1725284804_25456
000291120 3367_ $$2BibTeX$$aARTICLE
000291120 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000291120 3367_ $$00$$2EndNote$$aJournal Article
000291120 500__ $$a#LA:E055# / 2024 Sep;169(2):329-340
000291120 520__ $$aMesenchymal stromal cells (MSCs) within the glioblastoma microenvironment have been shown to promote tumor progression. Tumor Treating Fields (TTFields) are alternating electric fields with low intensity and intermediate frequency that exhibit anti-tumorigenic effects. While the effects of TTFields on glioblastoma cells have been studied previously, nothing is known about the influence of TTFields on MSCs.Single-cell RNA sequencing and immunofluorescence staining were employed to identify glioblastoma-associated MSCs in patient samples. Proliferation and clonogenic survival of human bone marrow-derived MSCs were assessed after TTFields in vitro. MSC' characteristic surface marker expression was determined using flow cytometry, while multi-lineage differentiation potential was examined with immunohistochemistry. Apoptosis was quantified based on caspase-3 and annexin-V/7-AAD levels in flow cytometry, and senescence was assessed with ß-galactosidase staining. MSCs' migratory potential was evaluated with Boyden chamber assays.Single-cell RNA sequencing and immunofluorescence showed the presence of glioblastoma-associated MSCs in patient samples. TTFields significantly reduced proliferation and clonogenic survival of human bone marrow-derived MSCs by up to 60% and 90%, respectively. While the characteristic surface marker expression and differentiation capacity were intact after TTFields, treatment resulted in increased apoptosis and senescence. Furthermore, TTFields significantly reduced MSCs' migratory capacity.We could demonstrate the presence of tumor-associated MSCs in glioblastoma patients, providing a rationale to study the impact of TTFields on MSCs. TTFields considerably increase apoptosis and senescence in MSCs, resulting in impaired survival and migration. The results provide a basis for further analyses on the role of MSCs in glioblastoma patients receiving TTFields.
000291120 536__ $$0G:(DE-HGF)POF4-315$$a315 - Bildgebung und Radioonkologie (POF4-315)$$cPOF4-315$$fPOF IV$$x0
000291120 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000291120 650_7 $$2Other$$aGlioma
000291120 650_7 $$2Other$$aMesenchymal stem cells
000291120 650_7 $$2Other$$aMesenchymal stromal cells
000291120 650_7 $$2Other$$aTumor microenvironment
000291120 7001_ $$aKückelhaus, Jan$$b1
000291120 7001_ $$aDiebold, Martin$$b2
000291120 7001_ $$aWuchter, Patrick$$b3
000291120 7001_ $$aHuber, Peter E$$b4
000291120 7001_ $$aSchnell, Oliver$$b5
000291120 7001_ $$aSankowski, Roman$$b6
000291120 7001_ $$aPrinz, Marco$$b7
000291120 7001_ $$0P:(DE-HGF)0$$aGrosu, Anca-Ligia$$b8
000291120 7001_ $$0P:(DE-HGF)0$$aHeiland, Dieter Henrik$$b9
000291120 7001_ $$0P:(DE-He78)8d52e7ff1ccaac7dbf0232fdcb0168bd$$aNicolay, Nils H$$b10$$udkfz
000291120 7001_ $$0P:(DE-He78)80e100a16534f5fc67f7436ee67a47f9$$aRühle, Alexander$$b11$$eLast author$$udkfz
000291120 773__ $$0PERI:(DE-600)2007293-4$$a10.1007/s11060-024-04740-0$$n2$$p329-340$$tJournal of neuro-oncology$$v169$$x0167-594X$$y2024
000291120 8564_ $$uhttps://inrepo02.dkfz.de/record/291120/files/s11060-024-04740-0.pdf
000291120 8564_ $$uhttps://inrepo02.dkfz.de/record/291120/files/s11060-024-04740-0.pdf?subformat=pdfa$$xpdfa
000291120 909CO $$ooai:inrepo02.dkfz.de:291120$$pVDB
000291120 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000291120 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000291120 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8d52e7ff1ccaac7dbf0232fdcb0168bd$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000291120 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)80e100a16534f5fc67f7436ee67a47f9$$aDeutsches Krebsforschungszentrum$$b11$$kDKFZ
000291120 9131_ $$0G:(DE-HGF)POF4-315$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vBildgebung und Radioonkologie$$x0
000291120 9141_ $$y2024
000291120 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2023-08-20$$wger
000291120 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2023-08-20$$wger
000291120 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2023-08-20$$wger
000291120 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ NEURO-ONCOL : 2022$$d2023-08-20
000291120 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-20
000291120 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-20
000291120 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-20
000291120 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-08-20
000291120 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-20
000291120 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-08-20
000291120 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-08-20
000291120 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2023-08-20
000291120 9202_ $$0I:(DE-He78)E055-20160331$$kE055$$lE055 KKE Molekulare Radioonkologie$$x0
000291120 9201_ $$0I:(DE-He78)FR01-20160331$$kFR01$$lDKTK Koordinierungsstelle Freiburg$$x0
000291120 9201_ $$0I:(DE-He78)E055-20160331$$kE055$$lE055 KKE Molekulare Radioonkologie$$x1
000291120 980__ $$ajournal
000291120 980__ $$aVDB
000291120 980__ $$aI:(DE-He78)FR01-20160331
000291120 980__ $$aI:(DE-He78)E055-20160331
000291120 980__ $$aUNRESTRICTED